Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease

Circulation

Volumn 94, Issue 2, 1996, Pages 151-157

  Böcker, Dirk ^a,b   Haverkamp, Wilhelm ^a   Block, Michael ^a   Borggrefe, Martin ^a   Hammel, Dieter ^a   Breithardt, Günter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG EFFICACY; FEMALE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029899696     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.2.151     Document Type: Article

References (50)

1. Senges J, Lengfelder W, Jauernig R, Czygan E, Brachmann J, Rizos I, Cobbe S, Kübler W. Electrophysiologic testing of therapy with sotalol for sustained ventricular tachycardia. Circulation. 1984;69:577-584.
2. Nademanee K, Feld GK, Hendrickson J, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation. 1985; 72:555-564.
3. Steinbeck G, Bach P, Haberl R. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol. 1986;8:949-958.
4. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-1718.
5. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992;20:1056-1062.
6. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from 22 randomized controlled trials. JAMA. 1993; 270:1589-1595.
7. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol. 1993;72:280-287.
8. Mason JW, for the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993;329:452-458.
9. Mason JW, for the ESVEM Investigators. A comparison of electrophysiologic testing with Holier monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med. 1993;329:445-451.
10. Kehoe RF, MacNeil DJ, Zheutlin TA, Ezri MD, Nazari J, Spangenberg RB, Dunnington C, Lueken M. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. Am J Cardiol. 1993;72:56A-66A.
11. Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol. 1988;12:1568-1572.
12. Singh SN, Cohen A, Chen Y, Wish M, Thoben-O'Grady L, Peralba J, Gottdiener J, Fletcher RD. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. Am J Cardiol. 1988;62:399-402.
13. Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. J Am Coll Cardiol. 1989;13:145-152.
14. Mirowski M, Mower MM, Staewen WS, Tabatznik B, Mendeloff AI. Standby automatic defibrillator. Arch Intern Med. 1970;126:158-161.
15. Mirowski M, Mower MM, Staewen WS, Denniston RH, Mendeloff AI. The development of the transvenous automatic defibrillator. Arch Intern Med. 1972;129:773-779.
16. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik S, Fischell RE, Weisfeldt M. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980; 303:322-324.
17. Mirowski M, Reid PR, Winkle RA, Mower MM, Watkins L, Stinson EB, Griffith LSC, Kallman CH, Weisfeldt ML. Mortality in patients with implanted automatic defibrillators. Ann Intern Med. 1983; 98:585-588.
18. Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol. 1990;16:381-386.
19. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989; 13:1353-1361.
20. Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. Ann Intern Med. 1987;107:635-641.
21. Tchou PJ, Kadri N, Anderson J, Caceres JA, Jazayeri M, Akhtar M. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med. 1988;109:529-534.
22. Kim SG, Fisher JD, Furman S, Gross J, Zilo P, Roth JA, Ferrick KJ, Brodman R. Benefits of implantable defibrillators are overestimated by sudden death rates and better represented by the total arrhythmic death rate. J Am Coll CardioL 1991;17:1587-1592.
23. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation. 1994;89:1851-1858.
24. Kim SG. Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol. 1993;71:1213-1218.
25. Fogoros RN. The implantable defibrillator backlash. Am J Cardiol. 1991;67:1424-1427.
26. Connolly SJ, Yusuf S. Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. Am J Cardiol. 1992;69:959-962.
27. Furman S. AICD benefit. PACE Pacing Clin Electrophysiol. 1989;399-400.
28. Böcker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, Breithardt G. Do patients with an implantable defibrillator live longer? J Am Call Cardiol 1993;21:1638-1644.
29. Böcker D, Block M, Isbruch F, Fastenrath C, Castrucci M, Hammel D, Scheld HH, Borggrefe M, Breithardt G. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J. 1995;73:158-163.
30. Martinez Rubio A, Shenasa M, Chen X, Wichter T, Breithardt G, Borggrefe M. Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease. Am J Cardiol. 1994;73:357-360.
31. Borggrefe M, Trampisch HJ, Breithardt G. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias. J Am Coll Cardiol. 1988;12:140-149.
32. Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR. Prehospital ventricular fibrillation: prognosis and follow-up course. N Engl J Med. 1974;291:317-321.
33. Schaffer WA, Cobb LA. Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med. 1975;293:259-262.
34. Powell AC, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, Kelly E, Vlahakes GJ, Torchiana DF, Ruskin JN. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation. 1993;88:1083-1092.
35. Wever EFD, Hauer RNW, Van Capelle FJL, Tijssen JGP, Crijns HJGM, Algra A, Wiesfeld ACP, Bakker PFA, Robles de Medina EO. Randomized study of implantable defibrillator as first-choice therapy versus conventional postinfarct sudden death survivors. Circulation. 1995;91:2195-2203.
36. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, Franklin J, Scheinman MM, Griffin JC. Survival after implantation of the cardioverter defibrillator. Am J Cardiol. 1992;69:899-903.
37. The AVID investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID): rationale, design, and methods. Am J Cardiol. 1995;75:470-475.
38. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, for the CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol. 1993;72:109F-113F.
39. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol. 1993;72:103F-108F.
40. Bardy GH, Hofer B, Johnson G, Kudenchuk PJ, Poole JE, Dolack GL, Gleva M, Mitchell R, Kelso D. Implantable transvenous cardioverter-defibrillators. Circulation. 1993;87:1152-1168.
41. Neuzner J, for the European P2 Investigators. Clinical experience with a new cardioverter defibrillator capable of biphasic wave-form pulse and enhanced data storage: results of a prospective multicenter study. PACE Pacing Clin Electrophysiol. 1994;17:1243-1255.
42. Saksena S. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. J Am Coll Cardiol. 1994;23:1521-1530.
43. Block M, Breithardt G. Long-term follow-up and clinical results of implantable cardioverter-defibrillators. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1995:1412-1425.
44. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtell K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation. 1992;85(suppl I):I-131-I-139.
45. Grimm W, Flores BT, Marchlinski FE. Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation. 1993;87:1880-1888.
46. Edel TB, Maloney JD, Moore S, McGuinn WP, Gohn D, Williams D, Wilkoff BL, McCarthy P, Morant VA, Pearce G, Simmons TW, Trohman R, Firstenberg M, Castle LW. Six-year clinical experience with the automatic implantable cardioverter defibrillator. PACE Pacing Clin Electrophysiol. 1991;14:1850-1854.
47. Rankin AC, Hamilton L, Du D, Newell J, Garan H, Ruskin JN, McGovern BA. Predictors of induced arrhythmia suppression and long term efficacy of oral sotalol in patients with drug refractory ventricular arrhythmias. Br Heart J. 1991;66:108P. Abstract.
48. Lee RJ, Wong M, Sui A, Grogin HR, Fitzpatrick AP, Epstein LM, Scheinman MM. Long term efficacy and safety of electrophysiologic guided sotalol therapy for life threatening ventricular arrhythmias. J Am Coll Cordiol. 1994;24:322A. Abstract.
49. Böcker D, Block M, Isbruch F, Wietholt D, Breithardt G. Shocks during normal sinus rhythm in patients with endocardial defibrillation lead systems. Eur Heart J. 1993;14:167. Abstract.
50. Bardy GH, Troutman C, Poole JE, Kudenchuk PJ, Dolack GL, Johnson G, Hofer B. Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation. 1992;85:1689-1698.